Press Release FeedGet the RSS feed
Menu

Business Wire

PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

Business Wire

BESREMi (ropeginterferon alfa-2b njft), the first new FDA-approved treatment for essential thrombocythemia in nearly three decades, offers patients an alternative option beyond hydroxyurea and anagrelide

More than half of patients with polycythemia vera remained on first-line BESREMi at two years in real-world practice

BURLINGTON, Mass., October 19, 2026--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced six poster presentations at the 18th International Congress on Myeloproliferative Neoplasms, taking place October 29-30 in Brooklyn, New York.

The presentations span essential thrombocythemia (ET) and polycythemia vera (PV), with a particular focus on real-world treatment patterns and outcomes. Three retrospective analyses use U.S. claims and community oncology data to examine how patients with ET and PV are being treated in clinical practice, including patterns of BESREMi® (ropeginterferon alfa-2b-njft) utilization and treatment persistence in PV, characteristics of patients initiating first-line BESREMi or other cytoreductive therapies for PV, and treatment patterns and unmet needs among patients with ET.

"Across ET and PV, these data point to the same conclusion: current treatment approaches leave substantial unmet need, and patients would benefit from therapies that do more than only control blood counts," said Albert Qin, M.D., Ph.D., Chief Medical Officer at PharmaEssentia. "With BESREMi now approved for adults with ET or PV in the U.S., we have an opportunity to reshape how myeloproliferative neoplasms are treated. We will continue to build evidence beyond the clinical trial setting to help physicians bring BESREMi to the patients who stand to benefit most."

A systematic review and meta-analysis examine disease-specific long-term outcomes following first-line hydroxyurea in ET and PV. Two further presentations evaluate BESREMi's effect on JAK2 V617F allele burden. The first is an exploratory analysis of two Phase 3 studies comparing rapid versus slow BESREMi titration in Japanese patients with PV. The second is a multicenter retrospective analysis of real-world BESREMi use in Chinese patients with MPNs. BESREMi is designed to address the underlying disease by targeting disease-driving cells in the bone marrow, and the reductions in JAK2 V617F allele burden seen in the Japanese and Chinese analyses provide a molecular measure of that activity.

  1. FinanceWilliamsMarston Acquires ERP Services Practice from ChartedAcquisition expands the firm's ability to help clients transform their finance functions and provides a broader range of ERP solutions to support clients' evolving needs; Charted continues as an independent company focused on ERP-native AP automation BOSTON, October 19, 2026--WilliamsMarston , a natio
  2. Only 15% of Americans Surveyed Say Capitalism Is Working as It Should, According to Operation HOPE's Latest HOPE Insider SurveyDespite concerns about economic opportunity, 87% of respondents are hopeful about their financial futures, with optimism reaching a record high ATLANTA, October 19, 2026--Operation HOPE, a national nonprofit dedicated to helping low- and moderate-income Americans thrive in an ever-changing economy, tod
  3. Aerospace & defenseAltera CorporationAltera Brings Defense-Grade Capabilities Across the Agilex FPGA PortfolioScalable performance and rugged packaging support mission-critical aerospace and defense systems in harsh environments SAN JOSE, Calif., October 19, 2026--Altera Corporation, the largest pure-play FPGA provider with a full-spectrum portfolio, today announced the expansion of its Agilex FPGA and SoC FPG
  4. MediaiFIT Debuts Transform 90, a 90-Day At-Home Strength Program Led by Trainers Featured in MrBeast’s "Lose 150lbs Together, Win $250,000" VideoAfter guiding engaged couple Sara Mosby and Tre Fontana through their transformational journey together in the YouTube video viewed by millions, iFIT Trainers John Peel and Bree Cox bring their expert coaching approach to the new Transform 90 program, available now on iFIT. PARK CITY, Utah, October 19, 2026 --( BUSINESS W
  5. MediaGroup 1001 Insurance Names George Haj as Chief Communications OfficerZIONSVILLE, Ind., October 19, 2026--Group 1001 Insurance, an integrated, technology-driven financial services and insurance group, announced George Haj as Chief Communications Officer. Haj joins the executive leadership team and reports to President and CEO Dan Towriss. As Chief Communications Officer, Haj leads the corporate communications and content functions across the company's family of bran
  6. ChartedCharted Announces Full Focus on AP Automation, Sells ERP Services Practice to WilliamsMarstonCharted continues as an independent software company and forms a strategic partnership with WilliamsMarston BOSTON, October 19, 2026--Charted, a leading ERP-native AP automation software company, today announced it has sold its ERP Services practice to WilliamsMarston, a leading accounting, tax, techno